DWJ 1506
Alternative Names: DWJ-1506Latest Information Update: 29 Mar 2021
At a glance
- Originator Daewoong Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dyslipidaemias
Most Recent Events
- 04 Mar 2021 Preclinical trials in Dyslipidaemias in South Korea (unspecified route) before March 2021 (NCT04772443)
- 04 Mar 2021 Daewoong Pharmaceutical plans a phase III trial for dyslipidemia (NCT04772443)